Elodie Bousquet

Dr. Elodie Bousquet

Ophtalmopôle, Hôpital Cochin, Assistance Publique des Hopitaux de Paris
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
Elodie BousquetElodie Bousquet
Elodie Bousquet
MDMyriam Dhundass
Myriam Dhundass
MLMathieu Lehmann
Mathieu Lehmann
PRPierre-Raphaël Rothschild
Pierre-Raphaël Rothschild
VBVirginie Bayon
Virginie Bayon
FBFrancine Behar-Cohen
Francine Behar-Cohen

16 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Elodie BousquetElodie Bousquet
Elodie Bousquet
PDPierre Duraffour
Pierre Duraffour
LDLouis DEBILLON
Louis DEBILLON
SSSwathi Somisetty
Swathi Somisetty
DMDominique Monnet
Dominique Monnet
ABAntoine P. Brézin
Antoine P. Brézin
Birdshot chorioretinopathy (BSCR) is a bilateral chronic inflammation of the eye with no extraocular manifestations. BSCR affects middle-aged individuals from European descent and is strongly associated with the human leucocyte antigen (HLA)-A29 allele. The immune mechanisms involved are not fully understood, but recent advances have shown the role of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) in disease pathogenesis. Multimodal imaging, including fluorescein angiography, indocyanine angiography, fundus autofluorescence, and optical coherence tomography, are useful in confirming the diagnosis and monitoring disease activity. Visual field testing is also important to assess the disease progression. To date, there is no consensus for optimal treatment regimen and duration. Local and systemic corticosteroids can be used for short periods, but immunosuppressive or biological therapies are usually needed for the long-term management of the disease. Here, we will review publications focused on birdshot chorioretinopathy to give an update on the pathophysiology, the multimodal imaging, and the treatment of the disease.

1 February 2019 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
Elodie BousquetElodie Bousquet
Elodie Bousquet
MDMyriam Dhundass
Myriam Dhundass
RLRaphaël Lejoyeux
Raphaël Lejoyeux
ASAri Shinojima
Ari Shinojima
VKValérie Krivosic
Valérie Krivosic
RTRamin Tadayoni
Ramin Tadayoni

1 August 2017 in Ophthalmology
Verified
Journal Article
Closed access
ADAnna Dastiridou
Anna Dastiridou
Elodie BousquetElodie Bousquet
Elodie Bousquet
LKLaura Kuehlewein
Laura Kuehlewein
TTTudor Tepelus
Tudor Tepelus
DMDominique Monnet
Dominique Monnet
SSSRINIVAS R SADDA
SRINIVAS R SADDA

12 January 2024 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
SVShilo Voichanski
Shilo Voichanski
Elodie BousquetElodie Bousquet
Elodie Bousquet
NANeda Abraham
Neda Abraham
ASAhmad Santina
Ahmad Santina
MMMostafa Mafi
Mostafa Mafi
DSDavid Sarraf
David Sarraf

30 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Elodie BousquetElodie Bousquet
Elodie Bousquet
JPJulien Provost
Julien Provost
MZMarta Zola
Marta Zola
RSRichard F. Spaide
Richard F. Spaide
CMChadi MEHANNA
Chadi MEHANNA
FBFrancine Behar-Cohen
Francine Behar-Cohen
(1) Indocyanine green angiography (ICG-A) shows the presence of mid-phase hyperfluorescent area in central serous chorioretinopathy (CSCR). However, their exact meaning remains uncertain. (2) The clinical and multimodal imaging findings of 100 patients (133 eyes) with CSCR, including the enhanced-depth-imaging OCT (EDI-OCT), blue-light fundus autofluorescence (BAF), fluorescein and indocyanine green angiography (FA and ICG-A) findings were reviewed. Mid-phase hyperfluorescent plaques (MPHP) were defined as fairly well circumscribed hyperfluorescent regions during the midphase of the ICG-A. The association between MPHP and other clinical/imaging parameters was assessed using a multiple logistic regression analysis. (3) MPHP were detected in 59.4% of eyes with CSCR. The chronic form of the disease, the presence of irregular pigment epithelium detachments (PED) and the retinal pigment epithelium (RPE) changes seen on FA were associated with the presence of MPHP in the multivariate analysis (p = 0.015; p = 0.018 and p = 0.002; respectively). OCT showed RPE bulges or PED in 98.7% of areas with MPHP and BAF showed changes in 57.3% of areas with MPHP. (4) MPHP were associated with a chronic form of CSCR and colocated with PED or RPE bulges. MPHP should be recognized as a sign of early RPE dysfunction before it is detected with BAF.